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An increasing number of private clinics in Australia are marketing and providing autologous stem cell therapies to
patients. Although advocates point to the importance of medical innovation and the primacy of patient choice,
these arguments are unconvincing. First, it is a stark truth that these clinics are flourishing while the efficacy and
safety of autologous stem cell therapies, outside of established indications for hematopioetic stem cell transplantation,
are yet to be shown. Second, few of these therapies are offered within clinical trials. Third, patients with chronic
and debilitating illnesses, who are often the ones who take up these therapies, incur significant financial burdens
in the expectation of benefiting from these treatments. Finally, the provision of these stem cell therapies does not
follow the established pathways for legitimate medical advancement. We argue that greater regulatory oversight
and professional action are necessary to protect vulnerable patients and that at this time the provision of
unproven stem cell therapies outside of clinical trials is unethical.Introduction
Currently, a number of private clinics in Australia are
advertising and selling stem cell therapies to patients.
These therapies are largely untested and unproven and
the results of these treatments have not been published
in the scientific literature. As these therapies are gener-
ally not subsidized by the government or by private in-
surers, vulnerable patients who often have few other
options are consequently assuming the not insignificant
costs and the uncertain risks of these treatments in the
absence of clear evidence of their efficacy.
We argue that these practices need greater regulatory
scrutiny. This article begins with a brief examination of
current stem cell science and what we know about stem
cell therapy. We then describe the range and characteristics
of autologous cellular therapies being offered in Australia.
The article examines the existing regulation of these
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2015discipline, and consumer law) and the ethics of innovative
therapies. We conclude that the current practice of offer-
ing unproven cellular therapies outside of clinical trials is
unethical and that much more could be done to better
regulate this practice.The current science of stem cell therapy
Although stem cell therapies are likely to become an in-
creasingly used therapeutic modality in skin grafting and
corneal repair, the only adult stem cell therapy that is
currently accepted for therapeutic use as standard best
practice is hematopoietic stem cell transplantation
(HSCT) [1]. Autologous and allogeneic HSCT is used to
treat a wide range of hematological malignancies, auto-
immune diseases, and genetic conditions (Table 1) [2].
Adult hematopoietic and non-hematopoietic stem cells
are also being investigated in preliminary clinical trials
for the treatment of a range of diseases. A number of
preliminary trials have been published investigating the
use of stem cells to improve heart function [3], stroke
[4], peripheral arterial disease [5], and amyotrophic lat-
eral sclerosis [6]. A phase II trial under way in Australia
is investigating autologous HSCT for multiple sclerosis
(MS) [7], and mature results of the trial are not expectedl. The licensee has exclusive rights to distribute this article, in any medium, for 12
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Table 1 Diseases commonly treated with hematopoietic stem-cell transplantation
Autologous transplantation Allogeneic transplantation
Malignancies Multiple myeloma Acute myeloid leukemia
Non-Hodgkin’s lymphoma Acute lymphoblastic leukemia
Hodgkin’s disease Chronic myeloid leukemia
Acute myeloid leukemia Myelodysplastic syndromes
Neuroblastoma Myeloproliferative disorders
Ovarian cancer Non-Hodgkin’s lymphoma
Germ-cell tumors Hodgkin’s disease
Chronic lymphocytic leukemia
Multiple myeloma
Juvenile chronic myeloid leukemia
Other diseases Autoimmune disorders Aplastic anemia
Amyloidosis Paroxysmal nocturnal hemaglobinuria
Fanconi’s anemia
Black-fan diamond anemia
Thalassemia major
Sickle cell anemia
Severe combined immunodeficiency
Wiskott-Aldrich syndrome
Inborn errors of metabolism
Adapted from Copelan [2] (2006).
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patients who received intra-articular injections of autolo-
gous adipose-derived mesenchymal stem cells (MSCs)
for osteoarthritis (OA) showed improvement in pain and
in arthroscopic, histological, and radiological outcomes
[8]. However, this pilot study lacked a control group,
which is crucial to demonstrating the efficacy of such
treatments as there is a clearly demonstrated placebo ef-
fect in the treatment of OA [9]. Importantly, no ran-
domized, double-blinded, multicenter clinical trials of
sufficient statistical power have been published that pro-
vide generalizable clinical data demonstrating the effi-
cacy of adult stem cell therapies over currently available
standard practice [10].
Although the use of MSCs appears to be safe, further
evaluation with large-scale clinical trials is required to
determine the safety profile [11]. A number of risks are
known to be associated with autologous stem cell ther-
apies, including thrombosis, acute lung injury, infection,
benign tumor growth, and malignant transformation,
and many more things remain unknown [12,13]. Three
recent case reports highlight the uncertain risks of stem
cell therapy. In the first, a boy who received an intra-
thecal injection of human fetal stem cells developed a
brain tumor derived from the transplanted neural cells
4 years after treatment [14]. In the second, a patient
who received an olfactory mucosal cell transplantation
at the site of spinal cord transection presented with aspinal cord mass from the transplanted cells 8 years later
[15]. Third, a patient undergoing autologous stem cell
therapy for lupus nephritis by direct renal injection de-
veloped angiomyeloproliferative mass lesions at the site
of injection [16]. Additionally, serious adverse effects
after administration of autologous cells by intravenous
and intracardiac routes and into the central nervous sys-
tem have been reported [17-19].
The practice of private stem cell clinics in
Australia
Even though stem cell science is at a relatively early
stage and there are limited mature clinical data, adult
stem cell therapies are already being provided directly to
patients in private clinics across Australia. We identified
17 private clinics and three stem cell companies that
currently provide autologous adult stem cell therapies.
These clinics offer autologous stem cell therapies for a
wide range of diseases outside of clinical trials, including
OA and musculoskeletal pain; neurodegenerative disor-
ders such as muscular dystrophy and MS; stroke; retinal
neuropathy; spinal cord injury; headache and migraine;
asthma; autism; ‘facial rejuvenation’; and anti-aging. The
medical professionals who provide stem cell therapies in
these private clinics in Australia include cosmetic sur-
geons, sports medicine physicians, orthopedic surgeons,
and general practitioners, and specialists in the diseases
being treated in these clinics, such as neurologists,
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of these clinics have websites with detailed information
regarding treatments available, media coverage of the
clinic, health professional profiles, and the cost of
treatment.
A lack of reliable research
Seven of these clinics claim to participate in research re-
garding stem cell therapies. However, with one excep-
tion, the health professionals at these clinics appear not
to have published their findings in peer-reviewed jour-
nals. One publication (which lacked statistical analysis or
evidence of ethics approval and was published in a jour-
nal not indexed by Medline) described a ‘pilot study’ in-
volving six patients whose OA was treated at the clinic
[20]. In this regard, it is noteworthy that the clinic
claims to have provided treatment to more than 300 pa-
tients [21].
A blinded randomized controlled clinical trial of 40
patients with OA used technology provided by one of
the stem cell companies, but results are yet to be pub-
lished, although the trial status is listed as closed with
follow-up complete. The company released an interim
report of the results of this clinical trial, stating that
stem cell therapy had reduced pain scores in the treat-
ment arm; however, the results of the trial showed no
difference in the reduction of pain scores between the
treatment and placebo arms of the trial [22].
The use of narratives in advertising
The information available on the clinics’ websites com-
monly includes patient and doctor narratives describing
the ‘dramatic’ effect of autologous stem cell therapy.
Seven clinics provide selected patient testimonials, pre-
senting only those patients who have undergone ‘suc-
cessful’ stem cell treatments. Patients from four clinics,
along with their doctor, have appeared on local Austra-
lian current affairs television programs to describe the
benefits they have experienced following stem cell treat-
ment [23-27]. Celebrity patients, in particular, have fea-
tured prominently in television reports of stem cell
therapies, including a television presenter and model, a
rugby league player, a retired Australian test cricket
bowler, and a former Olympic volleyball player. Social
media has also been used to support individual patients
‘access’ to stem cell therapies, and one clinic allowed a
general practitioner to provide autologous stem cell
therapy to an 8-year-old boy with autism after his par-
ents used social media to raise the necessary funds [28].
Unsupported claims
On their websites and in media interviews, both the
clinics and the health professionals who provide stem
cell therapies frequently make claims about efficacy andsafety that cannot be supported by published evidence,
and any support for the veracity of these claims rests
solely on local, unpublished data collected at their own
clinic. One clinic advertises that stem cell therapy is a
‘proven’ therapy for joint pain [29] and other clinics
state that stem cell therapy is reliably effective [30] and
‘appears 100% safe’ [31]—a claim that is inconsistent
with the possibility of infection and the small possibility
of malignancy reported with stem cell therapies [32].
Three clinics also claim 80% to 90% efficacy of stem cell
therapy and no way of predicting those patients who are
‘non-responders’ to treatment [21,33,34]. Yet another
clinic claims that stem cell therapy can improve the
strength, energy, and stamina of patients with muscular
dystrophy [35] and relieve migraine in 98% to 99% of pa-
tients [35]. One company claims that a technology it
supplies can generate pluripotent stem cells from the pa-
tient’s peripheral blood [36].
Costs of treatment
Autologous stem cell therapies, without exception, are
expensive. The cost of intra-articular injection of stem
cell is at least $9,000 (excluding the costs of consultation
by the health professionals, cell storage, and subsequent
therapy). The cost of stem cell therapy for autism is
$12,000 [37]. The cost of cosmetic injections of stem cell
therapy varies from $750 to $2,500 depending on the
treatment. Three clinics offer payment plans for between
$60,000 and $70,000 which can be repaid over the
course of 84 months. In all cases, these costs are not re-
imbursed by Medicare, the financial scheme that covers
the costs of approved medical care in Australia.
The regulatory context in Australia
In Australia, the regulation of therapeutic goods, includ-
ing prescription, non-prescription, and complementary
medicines as well as medical devices, is overseen by the
Therapeutic Goods Administration (TGA) [38]. The
TGA regulates cell products, including blood products,
vaccines, and hematopoietic stem cells, used in allogen-
eic transplantation. However, the TGA has specifically
excluded from its regulatory jurisdiction human cells
that are collected from a patient who is under the clin-
ical care and treatment of a registered medical practi-
tioner if the cells are manufactured by that medical
practitioner for therapeutic application in a single treat-
ment [39]. Consequently, any registered medical practi-
tioners in Australia can offer autologous stem cell
therapy to patients for a single treatment or disease,
such as OA, completely outside of any form of regula-
tion by the TGA.
At the same time, autologous stem cell therapies are
regulated by the same mechanisms that regulate clinical
practice, including the Medical Board of Australia and
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(AHPRA) in accordance with the Health Practitioner
Regulation National Law [40]. The Medical Board of
Australia produces standardized guidelines and codes of
conduct for good clinical practice [40]. The AHPRA and
its co-regulatory partners investigate allegations of un-
professional conduct and poor performance. Sanctions
may be imposed on practitioners, such as suspending
medical registration, and fines may be imposed on health
professionals found guilty of professional misconduct or
unsatisfactory professional conduct [41]. In this regard, it
is noteworthy that, as of June 2014, three health practi-
tioners have been disciplined for providing stem cell ther-
apies, and one had his medical registration suspended for
three years. (In Medical Board of Queensland v Tarvydas
(2010) QCAT 246, a doctor was found guilty of unsatisfac-
tory professional conduct, had his registration cancelled,
and was prevented from reapplying for registration for
3 years for offering stem therapy for adhesive arachnoi-
ditis. Other health practitioners such as chiropractors
(Chiropractic Board of Australia v Hooper (Review and
Regulation) (2013) VCAT 878) and a Chinese health
specialist (Chinese Medicine Registration Board of Victoria
v Ghaffurian (Occupational and Business Regulation)
(2012) VCAT 478) have also been disciplined for offer-
ing stem cell-related therapies.)
The common law also provides a regulatory frame-
work through actions in negligence which can be
brought by patients who have suffered damage as a re-
sult of the medical care which is not supported by peer
professional opinion as being competent professional
practice [42]. Australian consumer law may also have
some role to play, as businesses are not allowed to make
false or misleading statements or representations regard-
ing the quality and standard of products either to the
consumer or through advertising or promotional mater-
ial [43,44]. For example, if a business predicts the health
benefits of a therapeutic device or health product but
has no evidence that such health benefits can be
attained, this would constitute misleading conduct [45].
It seems, therefore, that the regulation of these therapies
is weak and the regulatory mechanisms available are pri-
marily reactive, rather than proactive, as they require
complaints to be made and investigated before the sys-
tems will respond.
Ethics of innovative therapies
Medical therapies become an accepted part of standard
medical practice through two different pathways, either
following rigorous evaluation through research or fol-
lowing innovation occurring in the course of clinical
practice. The distinction between standard therapy, re-
search, and innovative therapies is important as they at-
tract different regulatory frameworks.Standard therapies are those therapies that have been
sufficiently tested and accepted by peer review or rele-
vant regulatory bodies [46]. Research is a systematic in-
vestigation to establish facts, principles, or knowledge
and a study of some matter with the objective of obtain-
ing or confirming knowledge [47]. There are two central
aspects to the definition of innovative therapies: (a) the
departure from standard medical therapy and (b) that
the therapy has not been validated by reliable research
methods or there is not enough available evidence to
support the safety and efficiency of the therapy required
for acceptance or approval from peers and regulatory
bodies [46,48,49]. In regard to both standard clinical
practice and innovative therapies, patient care is para-
mount, whereas in the research setting, although close
attention is still paid to protecting patients and promot-
ing their welfare, emphasis is also paid to generating
new knowledge through research with populations of pa-
tients who may or may not receive therapies that subse-
quently turn out to have little or no benefit and that
may be associated with significant harms [48].
Innovation is a useful and legitimate tool for advancing
the body of medical knowledge [46]. Many of the major
advances in surgery that are considered routine today,
such as laparoscopic surgery, were introduced through
innovation, with little regulatory oversight, rather than
through research [50-52]. Importantly, in Australia, the
introduction of new innovative surgical procedures is
not integrated into any regulatory framework as it falls
outside the ambit of major regulatory bodies such as the
TGA [53].
Innovative practice is currently regulated as clinical
practice through codes of conduct, internal review, dis-
ciplinary and investigational bodies such as AHPRA, and
medical negligence law. One concern regarding innova-
tive therapy is that it creates a potential conflict between
the patient’s best interests and the personal, professional,
and financial interests of the physician [48,54,55]. A dir-
ect conflict of interest arises if the physician has a vested
financial or non-pecuniary interest in demonstrating the
success of the innovative therapy because of, for ex-
ample, a financial stake in the intellectual property con-
nected to the innovative therapy or a professional or
academic interest in the success of the innovation
[48,49]. It is arguable that, for this and other reasons,
greater regulatory oversight is required to protect the
best interests of patients and the community.
The International Society for Stem Cell Research
(ISSCR) supports innovative stem cell therapies and pro-
vides a series of recommendations to clinicians imple-
menting innovative stem cell therapies. The ISSCR
recommends a number of extra criteria that should be
satisfied in order to legitimately use stem cells in the
context of innovation, such as a written protocol which
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and formal follow-up of patients. According to the
ISSCR Guidelines, such innovative therapies should be
supported by clinical and administrative leadership, be
carried out by appropriately qualified personnel, ensure
that patients give voluntary informed consent, provide
an action plan for adverse events, be appropriately in-
sured, and be provided as part of a commitment by the
researchers and scientists toward the generation and dis-
semination of generalizable knowledge [56]. The add-
itional requirements placed on innovative therapies
involving stem cells by the ISSCR are necessary, as
therapeutic stem cells and their derivatives can vary in
source, manufacture, processing, potency, storage, and
route of delivery and have special risks such as tumor-
genicity and permanent integration into recipients, and
the long-term activity of stem cells also requires that
there be long-term follow-up of patients [49].
Conclusion
Despite the lack of evidence for the use of stem cell
therapies in humans other than in the context of
hematopoietic transplantation, at least 17 private clinics
across Australia provide autologous stem cell therapies
for a wide range of diseases [57]. Most of these clinics
have sophisticated websites that create the impressions
that the therapy is evidence-based and rests on rigorous
scientific and clinical data [10]. For example, the web-
sites include the following: lists of conferences attended
by professionals; claims of having patented technologies
that do not appear to exist in the Australia patent data-
base; explicit claims that stem cell therapies are effective
along with disclaimers that the treatment is ‘experimen-
tal’ and outcomes may vary; references to clinical trials
that have not progressed in over 3 years and to ongoing
clinical trials that are not registered, by another clinic;
claims that clinics are authoritative and ‘expert’ because
the health professionals who work there are involved in
writing a code of conduct for stem cell therapies in con-
sultation with government and universities [58]; and
widespread use of supportive patient testimonials and
media reports regarding stem cell technologies and
omission of any reference to more circumspect publica-
tions about autologous stem cell therapies, such as those
produced by the National Health and Medical Research
Council (NHMRC) and the ISSCR [1]. What is striking
about these websites, therefore, is the way in which they
use speculation, anecdote, media reports, and patient
narrative instead of scientific evidence to promote stem
cell therapies [10].
The use of patient testimonials is particularly note-
worthy because testimonials have been shown to out-
weigh prospective patient concerns regarding the risks
of stem cell therapies [59]. The use of patient testimonialto advertise, market, and promote autologous stem cell
therapies also arguably contravenes Australian law and
related guidelines regarding the advertising of health ser-
vices [40,60-62].
The lack of published data about these treatments is
extremely concerning. Medical practitioners working at
these stem cell clinics have provided treatment to hun-
dreds of patients over a number of years but have not
published the findings in peer-reviewed journals listed
on PubMed. The lack of publications suggests both a
limited commitment to research (as opposed to com-
merce) and a lack of openness and transparency in com-
municating methods and results with the medical
community [63]. The high success rates of stem cell
therapy stated on the websites of stem cell clinics and
shared in media interviews may create a misconception
among patients that the procedure is standard clinical
practice [64]. In reality, of course, these claims are based
upon a pathophysiological rationale that is rarely made
explicit and upon local ‘data’ that have not been verified
through peer review or publication. We believe that the
claims set out by practitioners create an unreasonable
expectation of the safety and efficacy of stem cell therap-
ies, which therefore could be considered in breach of the
National Law as well as health-related advertising stan-
dards in Australia [40,60,65-67].
Given the lack of evidence of the efficacy of stem cell
therapies [1,10], the cost of these therapies is exorbitant.
The charges that patients pay are even more difficult to
justify given that the medical practitioners involved
stand to gain financially and professionally by promoting
and selling stem cell therapies directly to patients.
Innovation in clinical practice should, of course, be
encouraged. However, autologous stem cell therapies
provided to hundreds of patients in private clinics
across Australia rarely can be considered innovative
therapies. Innovative therapies should be limited to a
small number of ill patients who have no other alterna-
tives [56,63,68]. Innovative therapies should also be in-
dividualized to each patient [63]. The fact that patients
can go up to $70,000 in debt through a single clinic
further suggests that the clinics are large-scale com-
mercial operations and that they do not provide in-
novative therapies [68,69].
Likewise, the clinics that are offering autologous
stem cell therapies outside the context of established
hematopoietic transplantation are generally not engaged
in research or in building databases that may contribute
to the meaningful assessment of their efficacy. In general,
the provision of these therapies is not based upon an iden-
tifiable research question or hypothesis, nor approval by a
research ethics committee to conduct research on human
subjects. There is also no responsible dissemination of re-
search findings through publication.
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stem cell therapies outside of clinical trials be prevented
through appropriate regulation or oversight and that le-
gitimate innovation be encouraged and not hampered
by over-regulation. Furthermore, clinical innovation in
autologous stem cell therapies should be subject to sci-
entific and ethical review and have built-in patient pro-
tection [56,68].
Allowing the provision of unproven autologous stem
cell therapies to continue outside of clinical trials is
enormously problematic [55,69-71]. Firstly, these pa-
tients are exposed to infrequent but still largely un-
known risks. Secondly, the patients who receive these
treatments may be excluded from participation in clin-
ical trials because of the unknown effects of unproven
stem cell therapies [69]. Thirdly, undergoing stem cell
therapy may lead to a delay for patients seeking proven
beneficial therapies [69]. Finally, the manner in which
these clinics advertise and provide unproven therapies
arguably undermines the integrity of the medical pro-
fession and the research community [69] and the suc-
cessful translation of stem cell research into clinical
practice [63].
Greater oversight of autologous stem cell therapies in
Australia is required. A number of strategies could be
pursued. One option is for the TGA to repeal its exclu-
sion, so that autologous stem cell therapies would attract
the same regulatory safeguards as other therapeutic
goods. Policing of unsubstantiated claims on websites
and media appearances through consumer laws would
help to reduce the misconception that unproven stem
cell therapies are safe, efficacious, and established treat-
ments. Providing education and information for health
professionals about the realistic expectations about stem
cell therapies and the existence of clinics providing un-
proven and expensive stem cell therapies (as the
NHMRC has already done) may enable patients to make
better-informed decisions about these therapies [55]. In
particular, patients should be cautioned that just because
a stem cell therapy is offered in Australia does not make
it legitimate [55]. Education and information should also
be targeted at patients to empower them to take respon-
sibility for their health choices. However, the informa-
tion provided needs to reach a wider public audience
and so should harness the same media platforms as the
clinics themselves. A register of innovative stem cell
therapies might also provide a mechanism to assess new
stem cell therapies by evaluating the scientific and eth-
ical rationale before a clinician has the opportunity to
provide treatment to hundreds of patients without over-
sight and could facilitate both the long-term follow-up
of patients and distinction of legitimate from illegitimate
innovation. The medical profession itself should also
take responsibility to ensure that practitioners clearlystepping outside the bounds of ethical and responsible
clinical practice be properly and publicly reprimanded
through the professional regulator (AHPRA), so that sit-
uations in which cosmetic surgeons provide treatment
to patients with amyotrophic lateral sclerosis, OA, and
asthma simply do not occur.
Individuals suffering from incurable conditions will
often pursue any chance of hope. Private stem cell
clinics across Australia have been allowed to take advan-
tage of this vulnerable patient population because of the
absence of adequate regulation and oversight and the ap-
parent unwillingness of regulatory bodies and research
and health professionals to act on existing breaches of
practice [55,69]. Greater oversight and greater action are
necessary to prevent the exploitation of desperate pa-
tients, to protect the probity of the medical profession,
and to limit the cost to society as a whole.
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